NDA 020414 · US Army
Pyridostigmine Bromide
Pyridostigmine Bromide · Oral
Priority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Sep 26, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Feb 5, 2003
Approved uses
1
Original approval plus efficacy supplements
Registered trials
45
6 Phase 3, 6 recruiting
FAERS reports
1,907
1,327 serious, 177 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS WITH IMPROPER USE OF PYRIDOSTIGMINE BROMIDE After Exposure to Soman, Use Atropine and Pralidoxime Pyridostigmine bromide is for use as a pretreatment for exposure to soman nerve agent. Pyridostigmine bromide alone will not protect against exposure to soman. The efficacy of pyridostigmine bromide is dependent upon the rapid use of atropine and pralidoxime (2-PAM) after soman exposure [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ]. Always Use Protective Garment(s) Primary protection against exposure to chemical nerve agents is the wearing of protective garments including masks, hoods, and overgarments designed specifically for this use. Individuals must not rely solely upon pretreatment with pyridostigmine bromide and on the antidotes atropine and pralidoxime (2-PAM) to provide complete protection from poisoning by soman nerve agent [see Dosage...
What it is approved for
From the label in effect Dec 23, 2025.
Pyridostigmine bromide is indicated for pretreatment against the lethal effects of soman nerve agent poisoning in adults. Pyridostigmine bromide is intended for use in conjunction with protective garments, including a mask. At the first sign of nerve agent poisoning, pyridostigmine bromide should be stopped, and atropine and pralidoxime therapy started immediately. The evidence for the effectiveness of pyridostigmine bromide as pretreatment against soman-induced toxicity was derived from animal studies alone [see Clinical Studies (14) ] . FOR MILITARY MEDICAL USE ONLY Pyridostigmine bromide is a cholinesterase inhibitor indicated for pretreatment against the lethal effects of soman nerve agent poisoning in adults. ( 1 ) Pyridostigmine bromide is for use in conjunction with: Protective garments, including a gas mask, and Immediate atropine and pralidoxime therapy at the first sign of nerve agent poisoning. ( 1 )
Mechanism: Pyridostigmine is a reversible cholinesterase inhibitor.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- PYRIDOSTIGMINE BROMIDE · PYRIDOSTIGMINE BROMIDE 30MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Pyridostigmine" as an intervention, any sponsor and status, largest first.
- Pyridostigmine in Severe SARS-CoV-2 InfectionPivotal-lookingStatus unknown
Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranAcademic, hospital or other
NCT04343963 · 436 participants (planned) · Start Apr 4, 2020 · Primary completion Sep 30, 2020
Drug: Pyridostigmine Bromide; Placebo · For: COVID-19; SARS-CoV-2
Sites: Mexico City, Mexico
- Treatment of Orthostatic Hypotension in Autonomic FailurePivotal-lookingCompleted
Vanderbilt UniversityAcademic, hospital or other
NCT00223691 · 389 participants · Start Mar 2002 · Primary completion Jan 2017
Drug: Atomoxetine; Acarbose and 19 more · For: Autonomic Failure; Orthostatic Hypotension
Sites: Nashville, Tennessee
- The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand ThymectomyPivotal-lookingCompleted
First Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT01727193 · 290 participants · Start Sep 2012 · Primary completion Oct 18, 2021
Drug: Azathioprine; Leflunomide · For: Myasthenia Gravis
Sites: Guangzhou, China
- Sugammadex-Induced Clenching During Neuromuscular Blockade ReversalPivotal-lookingRecruiting
Wonkwang University HospitalAcademic, hospital or other
NCT06962007 · 240 participants (planned) · Start Jul 1, 2025 · Primary completion Sep 20, 2026
Drug: Sugammadex 1 mg/kg Group; Sugammadex 2 mg/kg Group and 2 more · For: Neuromuscular Blockade Reversal Agent; Perioperative Complications; Anesthesia, General and 3 more
Sites: Iksan, South Korea
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
NCT04353778 · 215 participants · Start Aug 3, 2020 · Primary completion Mar 27, 2026
Drug: Pyridostigmine; Placebos · For: HIV; Non-HIV; Vagus Nerve Dysfunction
Sites: New York, New York
- Testing Mestinon and Exercise in FibromyalgiaPivotal-lookingCompleted
Oregon Health and Science UniversityAcademic, hospital or other
NCT00535587 · 178 participants · Start Sep 2002 · Primary completion Jun 2008
Drug: pyridostigmine; Placibo · For: Fibromyalgia
Sites: Portland, Oregon
- LIFT: Life Improvement TrialPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT06366724 · 160 participants (planned) · Start Sep 10, 2024 · Primary completion Sep 2027
Drug: Pyridostigmine; Low-Dose Naltrexone · For: ME/CFS; Long COVID; PASC
Sites: Boston, Massachusetts
- Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)Pivotal-lookingCompleted
Seoul National University HospitalAcademic, hospital or other
NCT02171988 · 150 participants · Start Mar 2014 · Primary completion Feb 2016
Drug: Propranolol; Bisoprolol and 2 more · For: Postural Orthostatic Tachycardia Syndrome
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- myasthenia gravis192
- fatigue165
- drug ineffective145
- dyspnoea145
- off label use130
- asthenia121
- headache115
- diarrhoea113
- nausea96
- malaise90
- dizziness76
- fall72
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 16 |
| 2006 | 18 |
| 2007 | 19 |
| 2008 | 45 |
| 2009 | 47 |
| 2010 | 37 |
| 2011 | 53 |
| 2012 | 45 |
| 2013 | 15 |
| 2014 | 24 |
| 2015 | 50 |
| 2016 | 85 |
| 2017 | 80 |
| 2018 | 104 |
| 2019 | 78 |
| 2020 | 128 |
| 2021 | 128 |
| 2022 | 109 |
| 2023 | 177 |
| 2024 | 240 |
| 2025 | 241 |
| 2026 | 158 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pyridostigmine Bromide (Pyridostigmine Bromide)
2024 spending
$21.6M
Beneficiaries
62,621
258,983 claims
Per beneficiary
$345
$0.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $21,368,327 |
| 2021 | $19,665,656 |
| 2022 | $21,871,760 |
| 2023 | $25,410,334 |
| 2024 | $21,587,647 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pyridostigmine in chronic intestinal pseudo-obstruction - a systematic review.
Wilkie BD, Noori J, Johnston M, et al. · ANZ J Surg 2023 · Systematic Review
- Systematic literature review: treatment of postural orthostatic tachycardia syndrome (POTS).
Schiweck N, Langer K, Maier A, et al. · Clin Auton Res 2026 · Systematic Review
- The evidence for treatments for postural orthostatic tachycardia syndrome: a systematic review of randomized trials.
Kwok CS, Lee S, Hall M, et al. · Trends Cardiovasc Med 2025 · Systematic Review, Research Support, Non-U.S. Gov't
- Sugammadex in Colorectal Surgery: A Systematic Review and Meta-analysis.
Chen AT, Patel A, McKechnie T, et al. · J Surg Res 2022 · Meta-Analysis, Systematic Review
- Treatment for postpolio syndrome.
Koopman FS, Beelen A, Gilhus NE, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Prevention and Management of Supine Hypertension in Patients With Orthostatic Hypotension.
Moroi MK, Ruzieh M, Ahmed A, et al. · Am J Ther 2021 · Systematic Review
Sponsor: US Army
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.